Compare Repligen Corporation Common Stock (RGEN) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Sezzle Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Sezzle Inc trades at $122.62 (market cap $4.39B). The key difference: Repligen Corporation Common Stock is far larger — about 2.5× Sezzle Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Sezzle Inc for 15 Days on average.
| RGEN | SEZL | |
|---|---|---|
Market Cap | $11.14B | $4.39B |
Volume | 1,259,263 | 424,843 |
Sector | Health | Financials |
52-Week High | $194.57 | $188.55 |
52-Week Low | $102.87 | $50.97 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $11.02B | $4.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Sezzle (SEZL) trades at $130.05, down 0.33% today, with a bullish technical signal and strong support near $127. The company demonstrates robust fundamentals, with Q2 2026 revenue growth of 51.7% year-over-year and a net income margin of 30.35%. Recent product launches like Sezzle Send and SezzleCash are driving user growth, while analyst consensus remains positive with a $168 price target.
Outlook is favorable given sustained earnings beats and raised guidance, but risks include competitive pressures in the BNPL sector and elevated valuation multiples. The stock offers growth potential if execution continues, though overbought technical indicators suggest near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
